PMID- 29434705
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 15
IP  - 2
DP  - 2018 Feb
TI  - Identification of a progression-associated long non-coding RNA signature for 
      predicting the prognosis of lung squamous cell carcinoma.
PG  - 1185-1192
LID - 10.3892/etm.2017.5571 [doi]
AB  - Long non-coding RNAs (lncRNAs) have been indicated to have prognostic roles in 
      various cancer types. However, the association between lncRNAs and lung squamous 
      cell carcinoma (LSCC) progression, and the prognostic value of lncRNAs as a 
      marker for early detection of LSCC have not been systematically investigated. The 
      present study performed a genome-wide comparative analysis in order to determine 
      the expression profiles of 10,207 lncRNAs to investigate the expression patterns 
      between patients with early stages of LSCC (stage I-II) and those with late-stage 
      disease (stage III-IV). It was found that 114 lncRNAs were significantly 
      differentially expressed between late- and early-stage LSCC and therefore 
      associated with the progression of the malignancy. By focusing on 
      progression-associated lncRNAs, eight lncRNAs were found to be significantly 
      associated with overall survival of LSCC patients according to univariate Cox 
      proportional hazards regression analysis. These eight prognostic lncRNAs were 
      integrated into a progression-associated eight-lncRNA signature, which stratified 
      patients into two groups with significantly different overall survival (median 
      survival, 2.25 vs. 7.68 years; P=2.06x10(-5)). In addition, the prognostic value 
      of the progression-associated eight-lncRNA signature was independent of known 
      clinical factors. Functional analysis suggested that eight prognostic lncRNAs may 
      be involved in adipocytokine signaling pathway and glycerophospholipid 
      metabolism. Taken together, the progression-associated eight-lncRNA signature 
      identified by our study not only represents a candidate prognostic biomarker for 
      LSCC patients but also provides insight into the molecular mechanisms in the 
      progression of LSCC.
FAU - Wang, Yanyan
AU  - Wang Y
AD  - Department of Medical Oncology, Daqing Oilfield General Hospital, Daqing, 
      Heilongjiang 163001, P.R. China.
FAU - Yang, Fang
AU  - Yang F
AD  - Department of Medical Oncology, Daqing Oilfield General Hospital, Daqing, 
      Heilongjiang 163001, P.R. China.
FAU - Zhuang, Yongzhi
AU  - Zhuang Y
AD  - Department of Medical Oncology, Daqing Oilfield General Hospital, Daqing, 
      Heilongjiang 163001, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171127
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC5774407
OTO - NOTNLM
OT  - expression profiles
OT  - long non-coding RNAs
OT  - lung squamous cell carcinoma
OT  - prognosis
EDAT- 2018/02/13 06:00
MHDA- 2018/02/13 06:01
PMCR- 2017/11/27
CRDT- 2018/02/14 06:00
PHST- 2016/08/02 00:00 [received]
PHST- 2017/04/07 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/02/13 06:01 [medline]
PHST- 2017/11/27 00:00 [pmc-release]
AID - ETM-0-0-5571 [pii]
AID - 10.3892/etm.2017.5571 [doi]
PST - ppublish
SO  - Exp Ther Med. 2018 Feb;15(2):1185-1192. doi: 10.3892/etm.2017.5571. Epub 2017 Nov 
      27.